Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
News headlines Recursion Pharmaceuticals (RXRX) reported mixed Q2 2026 results, highlighting progress in its AI-driven drug discovery platform and partnerships, despite a significant drop in revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results